文献速递类风湿关节炎

习得性免疫抑制安慰剂反应减缓大鼠类风湿关节炎疾病进展

Learned Immunosuppressive Placebo Response Attenuates Disease Progression in a Rodent Model of Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2020-01-01

该研究在大鼠II型胶原诱导性关节炎模型中,采用味觉-免疫条件反射方案,将糖精(条件刺激)与环孢素A(非条件刺激)配对,随后在症状出现时以条件刺激加低剂量环孢素A(全治疗剂量的25%)进行记忆更新。结果显示,习得性免疫抑制联合低剂量环孢素A通过β-肾上腺素受体依赖机制,显著抑制疾病进展,其效果与全剂量药物治疗相当。

要点

  • 习得性免疫抑制联合25%全剂量环孢素A可显著降低关节炎评分和组织学炎症症状(P<0.05)。
  • 该效应通过β-肾上腺素受体依赖机制介导,效果与100%全剂量药物治疗相当。
  • 记忆更新程序可稳定习得性免疫反应,防止条件反应消退。

核心结论

  • 习得性免疫抑制通过β-肾上腺素受体介导,联合低剂量环孢素A可减缓大鼠胶原诱导性关节炎的疾病进展。

主要发现

  • 习得性免疫抑制联合低剂量环孢素A(全治疗剂量的25%)显著降低临床关节炎评分和组织学炎症症状(均P<0.05),效果与全剂量(100%)药物治疗相当。
  • 该效应通过β-肾上腺素受体依赖机制介导。

关键数值与推荐

  • 低剂量环孢素A为全治疗剂量的25%;临床关节炎评分和组织学炎症症状的组间比较P<0.05。

临床怎么用

  • 提示习得性免疫抑制联合低剂量免疫抑制剂可能作为慢性炎症性自身免疫病的支持性治疗方案,减少疾病加重。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with chronic inflammatory autoimmune diseases benefit from a broad spectrum of immunosuppressive and antiproliferative medication available today. However, nearly all of these therapeutic compounds have unwanted toxic side effects. Recent knowledge about the neurobiology of placebo responses indicates that associative learning procedures can be utilized for dose reduction in immunopharmacotherapy while simultaneously maintaining treatment efficacy. This study was undertaken to examine whether and to what extent a 75% reduction of pharmacologic medication in combination with learned immunosuppression affects the clinical outcome in a rodent model of type II collagen-induced arthritis. METHODS: An established protocol of taste-immune conditioning was applied in a disease model of chronic inflammatory autoimmune disease (type II collagen-induced arthritis) in rats, where a novel taste (saccharin; conditioned stimulus [CS]) was paired with an injection of the immunosuppressive drug cyclosporin A (CSA) (unconditioned stimulus [US]). Following conditioning with 3 CS/US pairings (acquisition), the animals were immunized with type II collagen and Freund's incomplete adjuvant. Fourteen days later, at the first occurrence of clinical symptoms, retrieval was started by presenting the CS together with low-dose CSA as reminder cues to prevent the conditioned response from being extinguished. RESULTS: This "memory-updating" procedure stabilized the learned immune response and significantly suppressed disease progression in immunized rats. Clinical arthritis score and histologic inflammatory symptoms (both P < 0.05) were significantly diminished by learned immunosuppression in combination with low-dose CSA (25% of the full therapeutic dose) via β-adrenoceptor-dependent mechanisms, to the same extent as with full-dose (100%) pharmacologic treatment. CONCLUSION: These results indicate that learned immunosuppression appears to be mediated via β-adrenoceptors and might be beneficial as a supportive regimen in the treatment of chronic inflammatory autoimmune diseases by diminishing disease exacerbation.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Lückemann L, Stangl H, Straub RH, et al. Learned Immunosuppressive Placebo Response Attenuates Disease Progression in a Rodent Model of Rheumatoid Arthritis. Arthritis Rheumatol. 2020. PMID: 31509354. doi:10.1002/art.41101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。